KV Pharma (KV.A) to Pay $17M to Settle Ethex Allegations, DoJ Says
Tweet
Share
E-mail
KV Pharmaceutical Company (NYSE: KV.A) will pay $17 million to resolve False Claims Act allegations that Ethex failed to advise the Centers for Medicare and Medicaid Services that two unapproved products did not qualify for coverage under federal health care programs, the Justice Department announced today.
Ethex is alleged to have submitted false quarterly reports to the government related to a pair of drugs, Nitroglycerin Extended Release Capsules (Nitroglycerin ER) and Hyoscyamine Sulfate Extended Release Capsules (Hyoscyamine ER).
Ethex is alleged to have submitted false quarterly reports to the government related to a pair of drugs, Nitroglycerin Extended Release Capsules (Nitroglycerin ER) and Hyoscyamine Sulfate Extended Release Capsules (Hyoscyamine ER).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Home Depot expands executive roles, grants $500K in restricted stock
- Winnebago Industries refinances credit facility, extends maturity to 2031
- Noodles & Company (NDLS) files $100M mixed shelf
Create E-mail Alert Related Categories
Corporate News, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
